Valproate, risperidone, and paliperidone: A case of valproate-induced hyperammonemic encephalopathy

Hyperammonemia is a well-known adverse effect of valproate that can progress to a potentially fatal condition known as valproate-induced hyperammonemic encephalopathy (VHE). VHE is more common when valproate is used in combination therapy with other antiepileptic medications. A growing number of cas...

Full description

Saved in:
Bibliographic Details
Published in:The mental health clinician 2024-02, Vol.14 (1), p.28-32
Main Authors: Wesselman, Kyle, Cavaliere, Vincent, Goyal, Rakesh, Anderson, Eric
Format: Article
Language:English
Subjects:
encephalopathy
paliperidone palmitate
risperidone
valproate
vhe
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Hyperammonemia is a well-known adverse effect of valproate that can progress to a potentially fatal condition known as valproate-induced hyperammonemic encephalopathy (VHE). VHE is more common when valproate is used in combination therapy with other antiepileptic medications. A growing number of case reports have pointed to a possible interaction with the antipsychotic risperidone leading to an increased risk of VHE. We present a case of VHE in which a 20-year-old male patient with bipolar affective disorder developed VHE when on concomitant valproate, risperidone, and paliperidone palmitate. On the seventh day of treatment with oral risperidone, oral divalproex sodium was added. Intramuscular paliperidone palmitate was initiated on day 13, and oral risperidone was discontinued after the second loading dose on day 16. The following day, the patient displayed worsening psychomotor retardation, swaying gait, drowsiness, and vomiting. The patient was found to have hyperammonemia and transferred to the emergency department for treatment of suspected VHE.
ISSN:2168-9709
2168-9709
DOI:10.9740/mhc.2024.02.028